Abstract
Background
This study was designed to determine whether a preoperative fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) (FDG-PET/CT) could be used as a guide for axillary node dissection (AND) or sentinel lymph node biopsy (SNB) in breast cancer patients.
Methods
Between February 2007 and April 2008, we performed FDG-PET/CT scans in 137 biopsy-proven breast cancer patients planning to have an SNB to select patients for either AND (PET/CT N+) or SNB (PET/CT N0). In performing SNB, we also performed additional non-SNB (ADD), which was enlarged at the lower axilla.
Results
Twenty-seven patients with positive scans underwent complete AND as a primary procedure, and 110 patients with negative scans underwent SNB + ADD. There were 8 cases of false negative scans, and no case of false positive scan. The overall sensitivity, specificity, positive predictive value, and overall accuracy of FDG-PET/CT in predicting axillary metastasis were 77.1%, 100%, 100%, and 94.2%, respectively. In a subset of 110 patients with SNB + ADD, 104 patients had histologically negative SN, and 6 patients had positive SN in frozen section. Among 110 SNB + ADD cases, there were only 8 cases (7.3%) of positive axillary basins in permanent biopsy, including two cases of late positives that had micrometastases in the SN only. Through selective SNB + ADD based on an FDG-PET/CT, we have spared 27 unnecessary SNBs (true positive scans).
Conclusions
FDG-PET/CT is a specific imaging modality for predicting axillary node metastasis, and allows for a selective approach to either AND or SNB. A selective SNB + ADD based on an FDG-PET/CT reduced both unnecessary SNBs and positive axillary basins, enhancing the identification rates of SN and the accuracy of SNB.
Similar content being viewed by others
References
Carmichael AR (2008) A randomized controlled clinical trial on sentinel node lymph node dissection versus axillary lymph node dissection: a matter of technique or patient selection? Ann Surg 248:895–896
Krag D, Weaver D, Ashikaga T et al (1998) The sentinel node in breast cancer: a multicenter validation study. N Engl J Med 339:941–946
Lovrics PJ, Chen V, Coates G et al (2004) A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 11:846–853
Kumar R, Jana S, Heiba SI et al (2003) Retrospective analysis of sentinel lymph node localization in multicentric palpable and non-palpable breast cancer. J Nucl Med 44:7–10
Wong SL, Edwards MJ, Chao C et al (2002) The effect of lymphatic tumor burden on sentinel lymph node biopsy results. Breast J 8:192–198
Vargas HI, Vargas MP, Venegas R et al (2003) Lymphatic tumor burden negatively impacts the ability to detect the sentinel lymph node in breast cancer. Am Surg 69:886–890
Keskek M, Balas S, Gokoz A et al (2006) Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer. Surg Today 36:1047–1052
Shivers S, Cox C, Leight G et al (2002) Final results of the department of defense multicenter breast lymphatic mapping trial. Ann Surg Oncol 9:248–255
Reske SN, Kotzerke J (2001) FDG-PET for clinical use: results of the 3rd German Interdisciplinary Consensus Conference. “Onko-PET III”, 21 July and 19 September 2000. Eur J Nucl Med 28:1707–1723
Kao CH, Hsieh JF, Tsai SC et al (2000) Comparison and discrepancy of 18F–2-deoxyglucose positron emission tomography and Tc-99 m MDP bone scan to detect bone metastasis. Anticancer Res 20:2189–2192
Kostakoglu L, Goldsmith SJ (2003) 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 44:224–239
Eubank WB, Mankoff DA, Vesselle HJ et al (2002) Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22:5–17
Bockisch A, Brandt-Mainz K, Gorges R et al (2003) Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 30:22–25
Ueda S, Tsuda H, Asakawa H et al (2008) Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 8:165
De Kanter AY, Van Eijck CHJ, Van Geel AN et al (1999) Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg 86:1459–1462
Sapino A, Cassoni P, Zanon E et al (2003) Ultrasonographically guided fine-needle aspiration of axillary lymph nodes: role in breast cancer management. Br J Cancer 88:702–706
Motomura K, Inaji H, Komoike Y et al (2001) Gamma probe and ultrasonographically-guided fine-needle aspiration biopsy of sentinel lymph nodes in breast cancer patients. Eur J Surg Oncol 27:141–145
Kuenen-Boumeester V, Menke-Pluymers M, De Kanter AY et al (2003) Ultrasound-guided fine needle aspiration cytology of axillary lymph nodes in breast cancer patients. A preoperative staging procedure. Eur J Cancer 39:170–174
Guller U, Nitzsche EU, Schipr U et al (2002) Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet! Breast Cancer Res Treat 71:171–173
Yang JH, Nam SJ, Lee TS et al (2001) Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol 31:1–6
Van der Hoeven JJ, Hoekstra OS, Comans EF et al (2002) Determinants of diagnostic performance of [F-18] fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236:619–624
Wahl RL, Siegel BA, Coleman RE et al (2004) Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the Staging Breast Cancer with PET Study Group. J Clin Oncol 22:277–285
Fehr MK, Hornung R, Varga Z et al (2004) Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 10:89–93
Avril N, Rose CA, Schelling M et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495–3502
Fournier K, Schiller A, Perry RR et al (2004) Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg 239:859–863
Langer I, Marti WR, Guller U et al (2005) Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 241:152–158
Barranger E, Grahek D, Antoine M et al (2003) Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 10:622–627
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, J., Lee, J., Chang, E. et al. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience. World J Surg 33, 943–949 (2009). https://doi.org/10.1007/s00268-009-9955-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-009-9955-z